Rebecca Jones is vice president of medical services at Imagen Technologies and clinical assistant professor of neuroscience in psychiatry at Weill Cornell Medicine in New York City.
Rebecca Jones
Vice president of medical services
Imagen Technologies
From this contributor
Review: ‘Uncommon Sense’ exquisitely explores autism’s sensory experiences
The play dexterously depicts the struggles — sensory and social — of four characters who occupy distinct places on the autism spectrum.
Review: ‘Uncommon Sense’ exquisitely explores autism’s sensory experiences
By
Rebecca Jones
5 December 2017 | 6 min read
Explore more from The Transmitter
Double-duty neurons in primary olfactory cortex pick up on more than just scent
The cells recognize not only odors, such as bananas and black licorice—but also images and words associated with those smells, according to single-neuron recordings from 17 people.
Double-duty neurons in primary olfactory cortex pick up on more than just scent
The cells recognize not only odors, such as bananas and black licorice—but also images and words associated with those smells, according to single-neuron recordings from 17 people.
By
Angie Voyles Askham
9 October 2024 | 7 min read
How neuroscience comics add KA-POW! to the field: Q&A with Kanaka Rajan
The artistic approach can help explain complex ideas frame by frame without diluting the science, Rajan says.
How neuroscience comics add KA-POW! to the field: Q&A with Kanaka Rajan
The artistic approach can help explain complex ideas frame by frame without diluting the science, Rajan says.
By
Olivia Gieger
9 October 2024 | 7 min read
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
By
Brendan Borrell, Ellie Kincaid
8 October 2024 | 3 min read